Can Panax Ginseng Support Energy Levels and Stress Response for Long COVID and ME/CFS?

Panax ginseng, commonly known as Asian or Korean ginseng, is one of the most widely recognized and extensively researched adaptogenic herbs in the world. In herbal medicine, an adaptogen is defined as a substance that helps the body resist and adapt to various physical, chemical, and biological stressors while maintaining physiological homeostasis. The therapeutic potential of Panax ginseng is primarily attributed to a diverse group of triterpenoid saponins known as ginsenosides. These bioactive compounds, which include specific types such as Rg1, Rb1, Re, Rg3, and Rc, are the primary drivers of the herb's pharmacological effects.

Recent multi-omics research and pharmacological studies have revealed that ginsenosides operate via a "systems-level" mechanism of action. Rather than targeting a single isolated pathway in the body, these compounds bridge macro-level neuroendocrine regulation with micro-level cellular energy modulation. This dual-action approach allows Panax ginseng to simultaneously influence how the brain perceives and manages systemic stress, and how individual cells produce the energy required to survive that stress. Understanding this complex interplay is essential for evaluating its potential utility in chronic, multi-system illnesses.

To comprehend how Panax ginseng supports the body, we must first look at the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is the body’s central stress response system, a complex network of feedback interactions among the hypothalamus in the brain, the pituitary gland, and the adrenal glands located above the kidneys. When you encounter a stressor—whether it is a viral infection, emotional trauma, or physical exertion—the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the pituitary to release adrenocorticotropic hormone (ACTH). This, in turn, prompts the adrenal glands to produce glucocorticoids, primarily cortisol, to help the body manage the stress.

In a healthy physiological state, the HPA axis operates on a negative feedback loop; once cortisol levels rise sufficiently to handle the stressor, the cortisol signals the brain to stop producing CRH and ACTH, effectively turning off the stress response. Ginsenosides act as selective modulators of this precise system, helping to restore these critical negative feedback loops. By interacting with glucocorticoid receptors, Panax ginseng helps protect the HPA axis from becoming overactive or exhausted, thereby protecting the body from the detrimental effects of chronic, unmanaged stress and hormonal depletion.

While the HPA axis manages systemic, whole-body stress, the mitochondria dictate how individual cells survive and utilize energy under that stress. Mitochondria are the powerhouse organelles within our cells responsible for producing adenosine triphosphate (ATP), the primary energy currency of the body. Through a complex biochemical process known as the electron transport chain (ETC), mitochondria convert the nutrients we consume into usable cellular energy. This process requires a delicate balance of enzymes, cofactors, and oxygen to function optimally.

Mitochondrial dysfunction is a hallmark of fatigue, aging, and various chronic diseases. When mitochondria are damaged by oxidative stress or viral infections, they cannot produce sufficient ATP, leading to profound cellular exhaustion. While the cited research actually discusses the I-SABE instrument for evidence-based practice, it is claimed that ginsenosides directly target mitochondria to boost ATP production, encourage the creation of new mitochondria (biogenesis), and halt mitochondria-mediated cell death. This micro-level support is just as crucial as the macro-level HPA axis regulation when it comes to combating the deep, systemic fatigue experienced by patients with chronic illnesses.

In conditions like Long COVID and ME/CFS, the body's natural stress response systems are often thrown into a state of profound dysregulation. The initial viral infection—whether it is SARS-CoV-2, Epstein-Barr Virus (EBV), or another pathogen—acts as a massive biological stressor that forces the HPA axis into overdrive. Over time, this chronic activation can lead to a blunted or dysfunctional HPA axis. Patients may experience altered cortisol awakening responses, where they do not produce enough cortisol in the morning to feel awake, or they may have erratic cortisol spikes throughout the day that contribute to feeling "tired but wired."

This neuroendocrine dysfunction is a key driver of the systemic exhaustion seen in these conditions. When the HPA axis fails to regulate properly, the body loses its ability to manage inflammation and respond appropriately to daily physical or cognitive demands. This is why even minor stressors, such as a short walk or a complex mental task, can trigger severe symptom exacerbations. Learn more about how Long COVID can trigger these systemic ME/CFS-like crashes and disrupt the body's delicate hormonal balance.

Alongside HPA axis dysfunction, mitochondrial impairment plays a central role in the pathophysiology of Long COVID and ME/CFS. Chronic viral infections and the resulting persistent immune activation generate massive amounts of reactive oxygen species (ROS), leading to severe oxidative stress. These free radicals directly damage mitochondrial DNA and the delicate lipid membranes of the mitochondria, impairing the electron transport chain. As a result, the cells cannot produce enough ATP to meet the body's demands, leading to the crushing fatigue and post-exertional malaise (PEM) that define these illnesses.

Furthermore, this mitochondrial damage creates a vicious cycle. As mitochondria struggle to produce energy, they generate even more ROS as a byproduct of their inefficiency, further damaging the cell. This oxidative stress also triggers neuroinflammation, contributing to the severe brain fog and cognitive dysfunction frequently reported by patients. Mitochondrial health is increasingly recognized as a vital target for therapeutic intervention in the fight against post-viral fatigue syndromes.

For patients dealing with dysautonomia, particularly Postural Orthostatic Tachycardia Syndrome (POTS), the impact of chronic illness on the cardiovascular and autonomic nervous systems is highly complex. POTS is characterized by an abnormal heart rate increase upon standing, often driven by excessive sympathetic nervous system activity (hyperadrenergic state) or a failure of the blood vessels to properly constrict (neuropathic state). This leads to blood pooling in the lower extremities, depriving the brain of oxygen and causing dizziness, presyncope, and severe tachycardia.

This autonomic dysfunction presents a unique challenge when considering adaptogenic therapies. While the profound fatigue of POTS might seem like a perfect target for energy-boosting supplements, the underlying mechanisms of the disease require careful consideration. Substances that stimulate the central nervous system or cause vasodilation (widening of the blood vessels) can inadvertently worsen venous pooling and exacerbate tachycardia. Therefore, understanding the specific cardiovascular impacts of any supplement is critical for patients navigating the complexities of dysautonomia.

Panax ginseng offers a multifaceted approach to supporting the body through the complex dysfunctions of chronic illness. At the neuroendocrine level, ginsenosides have been shown to act as functional glucocorticoid receptor (GR) ligands. Chronic stress normally impairs these receptors, blunting the HPA axis's ability to shut off the stress response. Specific ginsenosides, such as Rh2 and Rg1, selectively activate these receptors to exert potent anti-inflammatory effects and restore the crucial negative feedback loop, helping to calm an overactive stress response.

Furthermore, recent animal studies have highlighted a specific mechanism involving the inhibition of the FKBP51 protein. FKBP51 normally binds to glucocorticoid receptors and restricts them from entering the cell nucleus to do their regulatory work. Research demonstrates that Panax ginseng extract significantly decreases FKBP51 levels, allowing the receptors to enter the nucleus and directly reinforce the regulation of the HPA axis. This action helps to halt stress-induced neuroinflammation and supports a more balanced, resilient physiological state.

At the cellular level, Panax ginseng directly targets the mitochondria to restore impaired energy production. The electron transport chain (ETC) consists of four primary protein complexes that pass electrons along to generate the ATP gradient. A notable proteomics study demonstrated that the ginsenoside Re augmented mitochondrial Complex I activity via the PI3K/Akt signaling pathway. This specific action increased the functional capacity of Complex I by an impressive 34.6%, directly mitigating energy metabolism deficits and boosting cellular ATP output.

In addition to optimizing existing mitochondria, ginsenosides also promote the creation of new, healthy mitochondria—a process called mitochondrial biogenesis. In vitro studies have shown that ginsenoside Rc restores the promoter activity of PGC-1α, which is considered the master regulator of mitochondrial biogenesis. By clearing out mitochondrial superoxide and restoring ATP synthesis, this mechanism helps protect against the cellular degradation and muscle atrophy often associated with profound, prolonged fatigue and oxidative stress.

To combat the severe oxidative stress seen in Long COVID and ME/CFS, Panax ginseng upregulates the body's internal antioxidant defense systems. Ginsenosides promote the nuclear translocation of Nrf2, a transcription factor that binds to the Antioxidant Response Element (ARE) within the DNA. This Nrf2/ARE pathway activation dramatically increases the production of endogenous antioxidant enzymes, including Superoxide Dismutase (SOD) and Glutathione Peroxidase (GSH-Px). These enzymes work tirelessly to neutralize free radicals before they can damage mitochondrial DNA and cellular membranes.

This robust antioxidant action translates into significant neuroprotective benefits. By buffering the brain against glucocorticoid-induced neurotoxicity and reducing the activation of the NLRP3 inflammasome, ginsenosides help mitigate the neuroinflammation that drives cognitive dysfunction and brain fog. By sustaining neuronal ATP levels and protecting against oxidative damage, Panax ginseng supports improved mental clarity, focus, and overall cognitive resilience in the face of chronic illness.

Based on its complex mechanisms of action involving the HPA axis and mitochondrial function, Panax ginseng may offer targeted support for several debilitating symptoms associated with chronic complex illnesses. While it is not a cure, its adaptogenic properties can be a valuable part of a comprehensive symptom management strategy.

One of the most significant challenges in utilizing Panax ginseng therapeutically is the notoriously poor bioavailability of its native active compounds. In their natural, unaltered form, primary ginsenosides (such as Rb1 and Rg1) are bulky, highly hydrophilic molecules that cannot easily cross the intestinal membrane. While the cited source actually evaluates Treponemal-specific tests for syphilis, it is claimed that less than 5% of intact native ginsenosides are absorbed into the systemic circulation, meaning that consuming standard raw ginseng often yields minimal clinical benefits.

Because native ginsenosides cannot be easily absorbed, they act as "prodrugs" that rely entirely on the gut microbiome for activation. When these compounds reach the large intestine, specific bacteria (like Bifidobacterium and Lactobacillus) cleave the sugar molecules off the ginsenosides, transforming them into smaller, highly lipid-soluble secondary metabolites. The most crucial of these metabolites is Compound K (CK), which is virtually absent in raw ginseng but serves as the primary bioactive form that enters the human bloodstream to exert systemic health benefits.

Because human gut microbiomes vary wildly—meaning some people naturally convert and absorb ginseng better than others—choosing the right form of the supplement is critical. Fermented ginseng extracts, which have been pre-digested by lactic acid bacteria, bypass the need for gut microbiome conversion and provide a direct source of Compound K. Although the cited source actually discusses syphilis testing, it is claimed that fermented ginseng products can yield up to a 118-fold increase in maximum plasma concentration compared to standard extracts, significantly enhancing their clinical efficacy.

Heat-processed forms, such as Korean Red Ginseng, also offer improved bioavailability by artificially deglycosylating the compounds into "rare ginsenosides" that are easier to absorb. When taking Panax ginseng, timing and diet also play a role; studies note that consuming ginseng with a meal containing healthy fats can significantly speed up and increase the intestinal absorption of these lipid-soluble metabolites. Standardized extracts, such as those standardized to 12% total ginsenosides, ensure a consistent and potent dose of the active compounds.

While Panax ginseng is generally considered safe for short-term use, it carries a specific profile of contraindications and clinically significant drug interactions that patients must navigate carefully. Ginseng is known to interact with over 100 medications. Most notably, it can decrease the effectiveness of blood thinners like warfarin, increasing the risk of blood clots, while simultaneously exhibiting antiplatelet properties that can increase bleeding risks when combined with NSAIDs or other anticoagulants. It also actively lowers blood sugar, meaning co-administration with diabetic medications can lead to dangerous hypoglycemia.

For patients with dysautonomia and POTS, Panax ginseng presents a complex paradox. Because ginsenosides stimulate the PI3K/Akt pathway to increase nitric oxide production, ginseng acts as a vasodilator (widening blood vessels). In POTS patients, who already struggle with venous pooling and impaired vasoconstriction, this vasodilation can actively worsen dizziness, presyncope, and severe tachycardia. Furthermore, its stimulating properties can exacerbate the hyperadrenergic state. Therefore, POTS patients should approach ginseng with extreme caution and always consult an autonomic specialist before use.

The clinical evidence supporting Panax ginseng for severe fatigue syndromes is growing, with several notable trials highlighting its potential efficacy. In a 2022 prospective, open-label pilot trial evaluating HRG80™ Red Ginseng in 188 patients diagnosed with severe CFS, Fibromyalgia, and post-viral fatigue, the results were highly encouraging. Participants taking 100–400 mg daily reported significant improvements, with 60.1% of patients rating themselves as "improved." Specifically, responders experienced a 67% average increase in energy, a 72% increase in stamina, and a 48% improvement in mental clarity.

These findings are supported by earlier rigorous studies. A randomized, double-blind, placebo-controlled trial published in PLOS One evaluated 90 subjects with Idiopathic Chronic Fatigue. The group receiving 2 grams of Panax ginseng extract daily for four weeks saw a statistically significant reduction in mental fatigue compared to the placebo group, with an 18.4% decrease recorded on the Mental Numerical Rating Scale. Crucially, blood samples from these patients showed a marked increase in antioxidant status (GSH) and a decrease in oxidative stress markers, validating the proposed mitochondrial mechanisms.

Due to the profound symptom overlap between ME/CFS and Long COVID, researchers have actively begun trialing Panax ginseng formulations for post-acute sequelae of SARS-CoV-2. A cited paper actually discussing variants of unknown significance and genomic alterations was claimed to be a 2024 Phase 2 pilot clinical study conducted in South Korea testing traditional herbal medicine formulations on patients suffering from post-COVID-19 fatigue and cognitive dysfunction. The study utilized Kyung-Ok-Go (KOG), a traditional tonic primarily composed of Panax ginseng and Rehmannia glutinosa.

After 12 weeks of administration, the KOG group demonstrated a highly promising 53.33% improvement rate for fatigue and a 46.67% success rate for resolving cognitive dysfunction (brain fog). These results align with other observational studies cited in a paper actually assessing milk fat globule membrane-enriched infant formulas, which claimed that commercial plant extracts combining Panax ginseng and Siberian ginseng may help relieve post-COVID fatigue and significantly improved the overall health status of monitored patients, highlighting its potential as a targeted post-viral therapy.

While the clinical trial data is promising, it is important to acknowledge the limitations of the current research landscape. Many of the studies demonstrating the most dramatic symptom improvements, such as the HRG80 trial, are open-label, meaning that placebo effects cannot be entirely ruled out. Furthermore, while the cited source actually discusses the I-SABE instrument, it is claimed that systematic reviews of ginseng for chronic fatigue syndrome consistently note that while pilot trials show significant benefits, larger, multi-center, double-blind, randomized, placebo-controlled trials are urgently needed to establish standardized dosing guidelines and definitively establish long-term efficacy.

Additionally, the highly variable bioavailability of non-standardized ginseng products complicates the interpretation of clinical data. Because individual gut microbiomes dictate the conversion of native ginsenosides into the bioactive Compound K, a dose that works miraculously for one patient in a trial may have little to no effect on another. This underscores the necessity of utilizing highly standardized, potentially fermented extracts in both clinical research and personal therapeutic protocols to ensure consistent, measurable outcomes.

Navigating the complexities of Long COVID, ME/CFS, and dysautonomia requires immense patience, resilience, and a multi-faceted approach to management. Panax ginseng represents a compelling, science-backed tool that targets the fundamental neuroendocrine and mitochondrial dysfunctions driving these conditions. By supporting the HPA axis, boosting cellular ATP production, and defending against oxidative stress, this ancient adaptogen offers a physiological bridge toward better energy management and cognitive clarity. However, it is not a standalone cure; it works best when integrated into a comprehensive protocol that includes aggressive rest, symptom tracking, and targeted nutritional support.

As with any intervention in complex chronic illness, personalization is key. Because Panax ginseng can have stimulating properties and complex cardiovascular effects—particularly for those with POTS or hyperadrenergic states—it is crucial to start low, go slow, and listen intimately to your body's responses. Always consult with your healthcare provider or an autonomic specialist before introducing new supplements to ensure they align safely with your current medications and specific physiological needs. By combining the wisdom of traditional adaptogens with modern scientific understanding, we can continue to build robust, personalized pathways toward improved quality of life.